Mario E. Lacouture, MD, dermatologist, Memorial Sloan Kettering Cancer Center, discusses the impact on quality of life of dermatologic adverse events.
Neoadjuvant TAR-200 Plus Cetrelimab Safe in Cisplatin-Ineligible MIBC
Neal Shore, MD, FACS, discussed findings from the SunRISe-4 trial of TAR-200 and cetrelimab in muscle-invasive bladder cancer.
Read More
Advancing Melanoma Treatment: Hamid on Lifileucel's Role
In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.
Listen
Ocular Events With Mirvetuximab Show No Impact on QoL in Ovarian Cancer
Understanding and Treating Mucosal Melanoma
In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.
Tilsotolimod Combo Does Not Improve Outcomes in Refractory Melanoma
Tilsotolimod plus ipilimumab did not show benefit vs ipilimumab alone in anti–PD-1 refractory melanoma, despite prior positive phase 1/2 trial data.
Teclistamab, Daratumumab, Pomalidomide Is Feasible in Multiple Myeloma
Anita D'Souza, MD, discussed the results from the MajesTEC-2 and TRIMM-2 trials in patients with multiple myeloma.